Fierce Biotech
After ph. 2 readout, analysts herald ‘best-in-class potential’ for Maze kidney candidate as stock plummets
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its “best-in-class potential.” But many investors were racing for the exits Wednesday.